Researchers Trace 25 Gray-Market Peptides, Challenging Big Pharma Patent Claims
Updated
Updated · peterattiamd.com · Oct 18
Researchers Trace 25 Gray-Market Peptides, Challenging Big Pharma Patent Claims
3 articles · Updated · peterattiamd.com · Oct 18
Summary
A new review mapped the patent and drug-development histories of 25 widely sold gray-market peptides, testing the claim that mainstream pharma ignored them because they could not be patented.
The analysis targets compounds such as BPC-157, CJC-1295, TB-500, GLP-1 agonists, growth-hormone secretagogues and melanocortin peptides, asking whether they truly lack commercial-development ties.
Researchers argue the popular defense of these products flips missing clinical evidence into a selling point, suggesting weak data reflects industry disinterest rather than poor efficacy or safety evidence.
The report says many peptides can in fact be patented and have substantial links to traditional pharmaceutical development, undercutting a central gray-market narrative.
If Big Pharma didn't ignore gray-market peptides, what dark safety secrets caused them to abandon clinical trials for compounds like CJC-1295?
With GLP-1 drugs generating billions, are unregulated 'research' peptides truly hidden medical miracles, or just a dangerously profitable wellness scam?